Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$8.41B+11.50%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Luke Victor Miels
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 66,841
- Beta
- 0.29
- Country
- GB
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.04
Financials
Revenue
$8.41B+11.5%Net Income
$435.00M-46.2%EBITDA
$2.83B+71.9%Free Cash Flow
$2.21B+73.5%EPS (diluted)
$0.22-47.6%Shares Outstanding (diluted)
2.03B+3.6%Operating Expenses
$5.67BCash & Debt
$3.09BReturn of Capital
$1.04BRevenue by Segment (annual)
$8.96BDividend per Share
$0.45Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.67B | $5.72B | $2.82 |
| 2024 | $31.38B | $2.58B | $1.26 |
| 2023 | $30.33B | $4.93B | $2.44 |
| 2022 | $29.32B | $14.96B | $7.44 |
| 2021 | $24.70B | $4.38B | $2.74 |
| 2020 | $24.35B | $5.75B | $2.88 |
| 2019 | $33.75B | $4.64B | $2.34 |
| 2018 | $30.82B | $3.62B | $1.84 |
| 2017 | $30.19B | $1.53B | $0.78 |
| 2016 | $27.89B | $912.00M | $0.48 |
| 2015 | $23.92B | $8.42B | $4.36 |
| 2014 | $23.01B | $2.76B | $1.44 |
| 2013 | $26.50B | $5.44B | $2.82 |
| 2012 | $26.43B | $4.50B | $2.30 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GSK's reported EPS growth of 1.6% a year over 13 years.
- EPS in 5 years
- $3.06
- Implied price
- $39.72
- Return from $47.03
- -3.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $19.75 — -58.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -8.4% | -19.0% | -15.7% | -12.8% | -10.3% | -8.0% |
| -3.4% | -14.6% | -11.1% | -8.1% | -5.4% | -3.0% |
| 1.6% | -10.2% | -6.5% | -3.3% | -0.5% | 2.0% |
| 6.6% | -5.8% | -1.9% | 1.4% | 4.4% | 7.0% |
| 11.6% | -1.3% | 2.7% | 6.2% | 9.3% | 12.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (25)
- Newsglobenewswire.com·6d ago·Positive
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
View source ↗ - Newszacks.com·7d ago·Negative
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.
View source ↗ - Newszacks.com·7d ago·Negative
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
View source ↗ - Newsbusinesswire.com·8d ago·Neutral
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research …
View source ↗ - Newsseekingalpha.com·12d ago·Positive
GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care GSK NYSE: GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the company's senior vice president and global head of Translational and Development Sciences.
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape GSK NYSE: GSK Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company's senior vice president and global head of oncology research and development.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsreuters.com·21d ago·Negative
GSK strikes up to $750 million deal for cancer-targeting drug GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences.
View source ↗ - Newszacks.com·21d ago·Positive
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff GSK NYSE: GSK is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through upcoming HIV patent expirations, Chief Financial Officer Julie Brown said during a company discussion.
View source ↗ - Newsreuters.com·24d ago·Neutral
GSK to shut vaccine factory in Germany, putting 641 jobs at risk GSK said on Friday it will be shutting down a vaccine factory in Dresden, Germany, which its website showed produces flu and hepatitis shots, in the summer of 2027.
View source ↗ - Newszacks.com·25d ago·Neutral
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
View source ↗ - Newsproactiveinvestors.co.uk·32d ago·Neutral
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.
View source ↗ - Newsproactiveinvestors.co.uk·33d ago·Positive
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook the biotech's expand…
View source ↗ - Newszacks.com·33d ago·Positive
GSK to Advance mRNA Influenza Vaccine Into Phase III Development GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
View source ↗ - Newszacks.com·34d ago·Positive
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
View source ↗ - Newsreuters.com·35d ago·Positive
GSK to advance mRNA flu vaccine to late-stage trial GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than currently approved standard- and high-dose shots.
View source ↗ - Newsseekingalpha.com·40d ago·Neutral
GSK: Still One Of My Top Healthcare Picks H2 2026/Q1 2027 will be rich in catalysts. From the potential FDA approval of bepirovirsen, with a target action date of October 26, for the treatment of chronic hepatitis B, to the Phase 3 OCEAN study results. By the way, Hibsago [bepirovirsen] was approved by Japan's Ministry of Health, Labour, and Welfare on August 24.
View source ↗ - Newszacks.com·42d ago·Neutral
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
View source ↗ - Newsreuters.com·43d ago·Negative
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy GSK said on Monday its experimental chronic hepatitis B drug received its first global approval in Japan, and a key cancer therapy was granted a priority U.S. regulatory review as a possible rectal cancer treatment.
View source ↗ - Newsproactiveinvestors.co.uk·47d ago·Negative
GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth GSK PLC (LSE:GSK, NYSE:GSK) got a grudging nod from Citi on Thursday, as the investment bank lifted its earnings forecasts for the drugmaker but stopped well short of a buy call. The shares edged up 0.31% to 1,922p as Citi kept its 'neutral' rating, tweaking its model after GSK's Accelerate Growth event and second-quarter results.
View source ↗ - Newscnbc.com·55d ago·Positive
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $1.37 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$1.36 vs $1.27beat
- Wed, Apr 29$1.24 vs $1.16beat
- Wed, Feb 4$0.68 vs $0.64beat
- Wed, Oct 29$1.48 vs $1.26beat
- Wed, Jul 30$1.23 vs $1.12beat
- Wed, Apr 30$1.13 vs $1.08beat
Estimates and results for GSK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (298d later)Buy$1,001 - $15,000
- Robert Aderholthouse · AL04 · disclosed Sep 11, 2025 (45d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed May 13, 2025 (22d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (45d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Nov 27, 2024 (2d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Nov 16, 2023 (31d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 12, 2023 (39d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 11, 2023 (38d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Apr 4, 2023 (34d later)Sell$50,001 - $100,000
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 8, 2022 (29d later)Buy$15,001 - $50,000
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 8, 2022 (30d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 8, 2022 (34d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.